I get some version of this question almost every week now, usually from someone already on a GLP-1 medication or seriously considering one: "I saw something about Ozempic and depression — should I be worried?"
It's a fair question, and the honest answer is more interesting than a simple yes or no. The story on GLP-1s and mental health has actually changed a lot in the last two years, and I think it's worth walking through what happened, because the current picture looks pretty different from the headlines that started this conversation.
Where the concern came from
Back in 2023, regulators started receiving scattered reports of suicidal thoughts in people taking semaglutide. The European Medicines Agency opened a formal investigation that July. A later analysis of the World Health Organization's global adverse-event database found that semaglutide specifically — not liraglutide, an older GLP-1 — was reported in connection with suicidality and self-harm more often than expected, and that signal got stronger when someone was also on an antidepressant or a benzodiazepine.
That's worth taking seriously, and it's exactly the kind of thing regulators are supposed to chase down. But it's also a specific kind of evidence with real limits: these were spontaneous reports, the kind anyone can file, not a controlled study. They can be skewed by media attention, by the fact that people with obesity or diabetes already have higher baseline rates of depression, and by how often someone is in front of a doctor to begin with. Spontaneous reports are good at raising a question. They can't answer it.
What the actual investigations found
Both the FDA and the EMA ran the data down. The FDA's review, published in January 2024, found no causal link. The EMA's own safety committee reached the same conclusion that April, after reviewing nonclinical studies, clinical trial data, postmarketing surveillance, and two separate electronic health records analyses. Their conclusion: no update to the drug labels was warranted.
Since then, more data has come in, including a few results I think are genuinely reassuring in a specific way most of the earlier studies weren't. A pooled analysis of the major semaglutide weight-loss trials found no increased depression or suicidal ideation compared to placebo, and a large Swedish cohort study found no association with suicide, self-harm, depression, or anxiety. Here's the catch with both of those: they mostly excluded people with a recent major depressive episode or a serious psychiatric history — which is to say, they were reassuring about the population least likely to be at risk in the first place, not the population everyone was actually worried about.
That gap is why a 2026 study published in The Lancet Psychiatry matters so much to me. It followed over 95,000 people who already had depression or anxiety, comparing periods when they were taking a GLP-1 to periods when they weren't. Semaglutide was associated with a 42% lower risk of their mental illness getting worse, with similar reductions specifically for depression and anxiety. That's an association, not proof of cause and effect — but it's reassuring data about precisely the people earlier studies couldn't tell us much about.
By January 2026, the FDA asked manufacturers to remove the suicidal ideation and behavior warning from semaglutide and tirzepatide's weight-loss labels entirely, citing a comprehensive review that found no increased risk and aiming for consistent labeling across the whole drug class.
So is it actually fine? Mostly — with one real caveat
I don't want to oversell the reassurance, because there's a thread running through almost all of this research: patients already on antidepressants or benzodiazepines, or with an existing psychiatric history, keep showing up as the group where the signal is strongest and the data is thinnest. The most comprehensive recent review of this evidence put it plainly — the medications as a class don't appear to increase psychiatric risk, but whatever residual risk exists is probably concentrated in people with pre-existing psychiatric vulnerability, and that group deserves individualized screening before starting and closer monitoring while on treatment. That's not a reason to avoid these medications if they're otherwise a good fit for you. It's a reason to make sure your prescriber actually knows your psychiatric history before you start.
The part nobody warns you about: food noise
Separate from the safety question, there's a psychological shift with GLP-1s that I think deserves more attention than it gets, and it's not a bad thing — it's just unexpected. Patients describe losing what's been nicknamed "food noise": the constant, intrusive background hum of thinking about food that isn't actually about hunger. In a recent patient survey, the share of people describing constant food thoughts dropped from 62% before treatment to 16% on it, and most described feeling genuinely better for it.
Here's the part worth sitting with, though. If food was ever functioning as a coping mechanism — something that quieted anxiety or filled an emotional gap — quieting the food noise can also quiet that coping mechanism. Some patients feel lighter in every sense. Others are surprised to find other feelings surfacing once the noise clears, feelings the eating had been managing without anyone quite realizing it. Neither reaction is wrong, but it's exactly the kind of shift that's worth having a mental health professional in the loop for, not because something went wrong, but because it's real psychological territory, not just a side effect of weight loss.
What I'd actually want you to take from this
If you're on a GLP-1 or thinking about starting one, and you have a history of depression, anxiety, or a complicated relationship with food, that's not a reason to rule it out. It's a reason to make sure the people managing your metabolic health and your mental health are actually talking to each other — which is exactly why I built the weight management program at Bailey Psychiatry the way I did, with psychiatric screening built in from the start rather than bolted on afterward.
Ready to feel like yourself again? [Book a consultation.] Virtual psychiatric and weight management care for adults, licensed in Illinois, Virginia, Michigan, Florida, and New York.
A few questions I get asked a lot
Do GLP-1 medications cause suicidal thoughts? The best current evidence says no, as a general matter. Early spontaneous reports raised the question, but controlled studies and large registry data haven't found a causal link, and a 2026 study of over 95,000 people with existing depression or anxiety actually found semaglutide associated with a lower risk of their mental illness worsening. The residual concern seems concentrated in people with significant pre-existing psychiatric vulnerability, which is why screening before starting matters.
Why did the FDA remove the suicide warning in 2026? In January 2026, the FDA asked manufacturers to remove the suicidal ideation and behavior warning from semaglutide and tirzepatide's weight-loss labels, citing a comprehensive review that found no increased risk and aiming for consistent labeling across the entire GLP-1 drug class.
Can GLP-1 medications actually improve mood? There's genuine signal pointing that direction for some patients, particularly those with existing anxiety or depression, though it's association, not proof. Part of it may be metabolic, and part may be a more direct effect on mood-related brain circuits — researchers are still untangling the two.
What is "food noise," and does losing it affect mental health? Food noise is the constant, intrusive background thinking about food that isn't driven by actual hunger. Many patients on GLP-1s describe it quieting significantly, which usually feels like relief. For people who used eating to manage stress or difficult emotions, though, losing that noise can also surface feelings the eating had been covering for — which is worth watching for, not worrying about alone.
